3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bulbo-Spinal Atrophy, X-Linked
1
Biliary Tract Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Gemcitabine
97
130-nm albumin-bound paclitaxel
47
Albumin-Bound Paclitaxel
36
Oxaliplatin
27
Fluorouracil
26
Capecitabine
20
Taxes
19
Leucovorin
19
pembrolizumab
18
Cyclophosphamide
18
Irinotecan
16
Bevacizumab
12
fludarabine
11
Nivolumab
11
Cetuximab
11
Cisplatin
10
durvalumab
8
Radiotherapy
8
spartalizumab
7
aldesleukin
7
Erlotinib Hydrochloride
7
Drug Therapy
7
avelumab
6
Radiosurgery
6
Paclitaxel
6
irinotecan sucrosofate
5
folfirinox
5
Ipilimumab
5
Injections
5
ALT-803
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Pancreatic Neoplasms
×
AZD5305
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled